Latest From Illumina Inc.
The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.
Privately-held BC Platforms is one of the networked groups leading the way in clinical genomics data management. Its CEO tells Scrip how the company's foundational start in Finland 21 years ago allowed it to create a critical mass from which it is now expanding globally in the quest to better understand the pathogenic mechanism of diseases.
Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Illumina Inc.
- Senior Management
Francis deSouza, Pres. & CEO
Sam Samad, CFO
Mark Van Oene, SVP, Chief Commercial Officer
Garrett Hampton, PhD, EVP, Clinical Genomics
Omead Ostadan, EVP, Products & Ops
Mark Stapley, EVP, Strategy & Corp Dev
Mostafa Ronaghi, PhD, SVP, CTO
- Contact Info
Phone: (858) 202-4500
5200 Illumina Way
San Diego, CA 92122
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.